| Revenue growth | FY26 total revenue ₹385 Cr; API sales grew 24%. |
|---|---|
| Margins | Gross Margin improved to 55.52%; EBITDA margin rose to 22.57%. |
| Demand visibility | 135+ oncology products; available in 85% of target hospitals. |
Growth
FY26 revenues: Branded ₹140 Cr, CDMO ₹149 Cr, Exports ₹71 Cr. Branded segment 30% CAGR since FY21.
Outlook
Beta Vision 2030 targets 51% branded mix. FY27 expected as watershed for export registrations.
Risks
Regulatory dossier approvals for exports; competition from MNCs in the IVF segment.
Earnings Call filed with NSE, NSE: BETA. Summary written with AI assistance from the document.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,991.40
- Market cap
- ₹2,208 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 48.4×Sector 47.3×
- Promoter holding
- 59.10%-5.53% QoQ
- FII holding
- 1.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Business Update
Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.
Beta Drugs Annual General Meeting
Beta Drugs Limited has scheduled its 21st Annual General Meeting for September 30, 2026, at its registered office in Baddi, Himachal Pradesh.
Beta Drugs Management Change
Beta Drugs Limited announced the re-appointment of its Statutory Auditor and an Executive Director. These re-appointments are effective from September 2026 and January 2027, respectively.
Beta Drugs Board Meeting Outcome
Beta Drugs Limited announced its board meeting outcome, covering AGM arrangements, auditor appointments, and the re-appointment of its Whole-Time Director, Ashutosh Shukla.
Beta Drugs Board Meeting Date
Beta Drugs Limited has scheduled a board meeting for September 3, 2026. The agenda includes fixing the 21st AGM details and approving the Director’s Report.
Beta Drugs Capital Structure Change
Beta Drugs Limited approved the allotment of 35,383 bonus equity shares. These shares were issued to holders of Compulsorily Convertible Debentures following their conversion.